Eli Lilly and Company (LLY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $1.28T
Last updated: Nov 17, 2026 at 5:28 PM ET
Eli Lilly and Company (LLY) Statistics
Eli Lilly and Company (LLY) has a market cap of $1.28T and an enterprise value of $1.32T. Revenue grew 45.51% over the last 12 months from the 12 months before. Its trailing P/E of 44.3x is above its 10-year median of 30.3x.
Total Valuation
Enterprise value is 3.50% above the market cap, as debt exceeds cash.
| Market Cap | $1.28T |
|---|---|
| Enterprise Value | $1.32T |
| Latest price (Nov 17, 2026) | $1,415.43 |
Key Dates
The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 13, 2026.
| Next Earnings Date | Feb 2, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Last Ex-Dividend Date | Nov 13, 2026 |
| Next Payment Date | Dec 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 14.6x and 31.4x. Its year-end P/E ranged from 19.7x to 92.2x from 2016 to 2025.
| P/E Ratio | 44.3x |
|---|---|
| Forward P/E | 39.4x |
| P/S Ratio | 14.6x |
| Forward P/S | 13.9x |
| P/B Ratio | 31.4x |
| P/TBV Ratio | 102.9x |
| P/FCF Ratio | 64.2x |
| P/OCF Ratio | 41.6x |
| PEG Ratio | 1.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 35.4x EBITDA and 66.5x free cash flow.
| EV / Earnings | 47.9x |
|---|---|
| EV / Sales | 15.3x |
| EV / EBITDA | 35.4x |
| EV / EBIT | 38.0x |
| EV / FCF | 66.5x |
Price Statistics
The stock is up 38.28% over 52 weeks and trades 13.13% above its 50-day average.
| Beta (1Y) | 0.32 |
|---|---|
| 52-Week Change | +38.28% |
| 1-Month Change | +14.25% |
| 3-Month Change | +10.68% |
| 6-Month Change | +38.78% |
| 5-Year Change | +456.42% |
| 10-Year Change | +1819.75% |
| Total Return (1Y) | +38.96% |
| Total Return (3Y CAGR) | +34.35% |
| Total Return (5Y CAGR) | +41.27% |
| Return vs SPY (1Y) | +26.08% |
| Max Drawdown (1Y) | -23.43% |
| Max Drawdown (3Y) | -34.47% |
| Sharpe Ratio (1Y) | 0.92 |
| Correlation with SPY (1Y) | 0.13 |
| 50-Day Average | $1,251.16 |
| 200-Day Average | $1,111.00 |
| 52-Week Range | $846.81 to $1,475.25 |
| RSI (14 Days) | 63.2 |
| Average Volume (20 Days) | 3.02M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.39x current liabilities, and total debt is 1.23x shareholder equity.
| Current Ratio | 1.39x |
|---|---|
| Quick Ratio | 1.00x |
| Debt / Equity | 1.23x |
| Debt / EBITDA | 1.34x |
| Debt / FCF | 2.52x |
Returns and Efficiency
Return on invested capital is 30.72% over the last 12 months, against a 5-year average of 22.27%.
| Return on Equity (ROE) | 68.49% |
|---|---|
| Return on Assets (ROA) | 18.63% |
| Return on Invested Capital (ROIC) | 30.72% |
| Return on Capital Employed (ROCE) | 34.40% |
| ROE (5Y Average) | 64.29% |
| ROA (5Y Average) | 12.81% |
| ROIC (5Y Average) | 22.27% |
| Asset Turnover | 0.66x |
| Inventory Turnover | 0.81x |
| Receivables Turnover | 3.55x |
| Cash Conversion Cycle | 401 days |
Taxes
Income tax took 20.68% of pretax income over the last 12 months.
| Income Tax (TTM) | $7.19B |
|---|---|
| Effective Tax Rate | 20.68% |
Scores
LLY has an Altman Z-Score of 8.89, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 8.89 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $86.46B over the last 12 months.
| Revenue | $86.46B |
|---|---|
| Revenue Growth (YoY) | +45.51% |
| Gross Profit | $72.31B |
| Operating Income | $34.88B |
| Pretax Income | $34.77B |
| Net Income | $27.58B |
| EBITDA | $36.94B |
| EBIT | $34.77B |
| Reported EPS (TTM) | $31.95 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 27.20% of the $148.07B in total assets.
| Cash and Equivalents | $4.88B |
|---|---|
| Total Debt | $49.50B |
| Net Debt | $44.62B |
| Net Debt Per Share | $50.03 |
| Working Capital | $18.27B |
| Shareholder Equity | $40.27B |
| Book Value Per Share | $45.10 |
| Tangible Book Value | $12.31B |
| Tangible Book Per Share | $13.75 |
| Total Assets | $148.07B |
| Total Liabilities | $107.80B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $10.98B of capital spending, operating cash flow left $19.66B of free cash flow.
| Operating Cash Flow | $30.64B |
|---|---|
| Capital Expenditures | $10.98B |
| Free Cash Flow | $19.66B |
| FCF Per Share | $22.06 |
| Depreciation and Amortization | $2.17B |
| Dividends Paid | $5.98B |
| Share Repurchases | $5.84B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 40.34%, against a 5-year average of 27.07%.
| Gross Margin | 83.63% |
|---|---|
| Operating Margin | 40.34% |
| Pretax Margin | 40.21% |
| Net Margin | 31.90% |
| EBITDA Margin | 42.73% |
| EBIT Margin | 40.21% |
| FCF Margin | 22.74% |
| Gross Margin (5Y Average) | 78.91% |
| Operating Margin (5Y Average) | 27.07% |
| Net Margin (5Y Average) | 22.42% |
Growth
Revenue grew 31.69% a year over 3 years, and EPS 45.01% a year.
| Revenue Growth (3Y CAGR) | +31.69% |
|---|---|
| Revenue Growth (5Y CAGR) | +21.58% |
| EPS Growth (3Y CAGR) | +45.01% |
| EPS Growth (5Y CAGR) | +25.01% |
| FCF Growth (3Y CAGR) | +16.11% |
| FCF Growth (5Y CAGR) | +11.91% |
| Operating Income Growth (3Y CAGR) | +54.53% |
| Book Value Per Share Growth (2Y CAGR) | +57.41% |
Dividends and Yields
LLY pays out 20.14% of earnings as dividends.
| Dividend Per Share (Annual) | $6.92 |
|---|---|
| Dividend Yield | 0.49% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +15.24% |
| Dividend Growth (5Y CAGR) | +15.18% |
| Payout Ratio | 20.14% |
| FCF Payout Ratio | 30.42% |
| Earnings Yield | 2.26% |
| FCF Yield | 1.56% |
| Buyback Yield | 0.46% |
| Shareholder Yield | 0.94% |
Peer Position
Against 9 similar companies, LLY has the 2nd highest P/E.
P/E RatioPeer median 19.8x
P/S RatioPeer median 4.9x
ROICPeer median 13.48%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.13%
Dividend YieldPeer median 2.69%
| P/E Ratio | 44.3x vs 19.8x median |
|---|---|
| P/S Ratio | 14.6x vs 4.9x median |
| ROIC | 30.72% vs 13.48% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +45.51% vs +6.13% median |
| Dividend Yield | 0.49% vs 2.69% median |
Analyst Forecast
Consensus estimates put revenue growth at 27.82% and EPS growth at 44.63% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +27.82% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +44.63% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LLY
What is LLY's market cap?
Eli Lilly and Company has a market cap of $1.28T. Its enterprise value, which adds debt and subtracts cash, is $1.32T.
What is LLY's P/E ratio?
Eli Lilly and Company has a trailing P/E ratio of 44.3x and a forward P/E of 39.4x.
How many shares of LLY are outstanding?
Eli Lilly and Company has 891.90M shares outstanding. The count is down 0.56% from a year earlier.
Does LLY pay a dividend?
Yes. Eli Lilly and Company pays $6.92 a share a year, a dividend yield of 0.49%.
How much debt does LLY have?
Eli Lilly and Company has $49.50B of total debt and $4.88B of cash and equivalents, a net debt position of $44.62B.
LLY pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts